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Introduction: The incidence of melanoma is dramatically increasing worldwide.  We 
hypothesized that the ratio of metastatic to examined lymph nodes (LNR) would be the 
most important prognostic factor for stage III patients. 
Methods: We retrospectively reviewed our institutional database of melanoma patients 
and identified 168 patients who underwent lymph node dissection (LND) for stage III 
disease between 1993 and 2007.  Patients were divided into 3 groups based on LNR 
(<10%, n= 93; 10-<25%, n=45; and >25%, n= 30).  Univariate and multivariate analysis 
was performed using Cox proportional hazards model. 
Results: The median survival time of the entire group of patients was 34 months.  The 
median number of positive nodes was 2 (range=1, 55), and the median number of 
examined nodes was 22 (range=5 - 123).  Tumor characteristics of the primary melanoma 
(such as thickness, ulceration, and primary site) were not significant predictors of 
survival in this analysis. By univariate analysis, LNR was an important prognostic factor.  
Patients with LNR 10-25% and >25% had decreased survival compared to those patients 
with LNR <10% (HR = hazard ratio = 2.0 and 3.1, respectively; p ≤0.005).  The number 
of positive lymph nodes also impacted on survival (p =0.001).  In multivariate analysis, 
LNR of 10-25% and >25% predicted survival (HR= 2.5 and 4.0, respectively). 
Conclusion: LNR is an important prognostic factor in patients undergoing LND for stage 
III melanoma.  It can be used to stratify patients being considered for adjuvant therapy 
trials and should be evaluated using a larger prospective database. 
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INTRODUCTION 
 
 Between the years of 1975 and 2005 the annual incidence in melanoma in the 
United States increased from 7.9 per 100,000 to 21.5 per 100,000, while the death rate 
has increased from 2.1 to 2.7 per 100,0001. It has been estimated that in fair-skinned 
populations the incidence is currently increasing by 3-7% per year worldwide.  
 Stage III melanoma is defined by the metastatic infiltration of 1 or more lymph 
nodes or by intra-lymphatic metastasis in the form of in-transit or satellite lesions. These 
criteria represent a heterogenous group of individuals with 5-year survival ranging from 
69% to as low as 13%. 2 Prognostic indicators which are used for TNM staging of stage 
III patients include the number of metastatic lymph nodes, the tumor burden within 
positive nodes (microscopic or macroscopic), the presence or absence of ulceration in the 
primary lesion, and the presence of in-transit or satellite metastasis.  
 Due to the high toxicity and variable response to adjuvant treatments for 
melanoma, it is essential to establish new prognostic indicators which can be used to 
direct the management of Stage III melanoma patients. While biologic and genetic 
markers have been identified, they are not yet available for widespread use. Thus there is 
a call for new, readily available clinical prognostic indicators. One factor which is 
consistently shown to be an important determinant of survival in stage III patients is 
increasing number of positive lymph nodes. 3, 4 Another prognostic factor which has 
become more prominent in many malignancies is the ratio of positive to total examined 
lymph nodes or lymph node ratio (LNR). 5, 6 
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 There is recent evidence that LNR is an important prognostic factor in 
malignancies such as gastric cancer, esophageal cancer, and breast cancer. Two recent 
reports from Japan and Spain have demonstrated that increasing LNR is a significant 
prognostic indicator for worse survival in gastric cancer 7, 8. A recent publication also 
demonstrated the importance of LNR in pancreatic cancer 9.  Finally, two recent studies 
demonstrated the importance of LNR in patients with melanoma undergoing radical 
lymph node dissection 5,10. In this study we hypothesize that the ratio of metastatic lymph 
nodes to total nodes excised is an independent prognostic indicator of survival in Stage 
III melanoma patients.  
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METHODS 
 After obtaining IRB approval, the Tumor Registry at Thomas Jefferson Hospital 
was queried to identify all patients who underwent lymph node dissection (LND) for 
stage III melanoma. Two-hundred sixteen patients were identified who met these criteria 
for the period of August 1993 to May 2007, and 168 patients had complete data (for most 
variables), and comprise our study cohort In this study, 93 patients (55%) underwent 
therapeutic LND based on clinical findings, 14 (8%) received prophylactic dissection, 
and 61 (36%) had a positive sentinel lymph node biopsy (SNB).  
 A three-level axillary lymph node dissection was most commonly employed 
(n=112, 52%).  A total of 68 patients (40%) underwent some combination of inguinal 
and/or iliac dissection. Eleven patients underwent cervical lymph node dissection alone 
(7%) and 5 patients had a combination of cervical and axillary dissection.   After 
dissection, all patients were followed with physical examination, history, blood work, and 
imaging which included alternating chest x-rays and cross-sectional imaging.  Follow-up 
was generally every 3 months for the first two years and then every 6 months thereafter.  
The median follow-up for the entire group was 26 months (range 0.5-152 months).   
 The following clinical and pathologic variables were collected for univariate and 
multivariate analysis: age (<50, ≥50), sex, year of surgery, site of primary tumor 
(head/neck, trunk, extremity), tumor thickness (≤1, 1 -≤2,  2 - < 4,  ≥4), ulceration (yes, 
no, or unknown), type of adjuvant treatment (vaccine, chemotherapy meds, IFM, 
combination, none/unknown), lymph node basin dissected (axillary, inguinal, iliac, 
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cervical, or combination), number of positive nodes (1, 2-3, ≥4 – AJCC stages N1, N2, 
and N3 respectively) and the ratio of histologically positive lymph nodes to total number 
of nodes examined - the Lymph Node Ratio (LNR) (The total number of excised nodes 
(continuous; and also categorical:  <20, 21-40, >40) are also presented in univariate 
analysis).  The lymph node ratio was categorized into 3 different groups based on the 
paper by Rossi et al 5--≤ 10% (group 1), 10 - <25% (group 2), and >25% (group 3).  
Survival was calculated from the date of lymph node dissection to date of last follow-up 
or death.  Patients were staged according to the AJCC 6th edition, although the majority 
of patients did undergo dissection prior to 2002 (n=122, 73%) when those guidelines 
were published.   
 Survival curves were generated using the Kaplan-Meier method. Univariate and 
multivariate analysis were preformed with the Cox proportional hazards model.  To 
determine the best variable to assess lymph node involvement, 3 separate multivariate 
models were fit, one with number of positive lymph nodes, one with lymph node ratio 
alone, and one model with both of these variables.  The Akaike Information Criterion, 
which is a measure of the goodness of fit of an estimated statistical model, was used to 
select the preferred model11.  Results with P values of less than 0.05 were considered 
statistically significant. 
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RESULTS 
 The average age of patients at time of LND was 57.9 years old (range = 18-86); 
there were 103 males and 65 females (ratio = 1.6:1). Primary tumors were most 
commonly located on the trunk (n = 86, 51%), followed by upper or lower extremity (n = 
74, 44%), and head and neck (n = 8, 5%), No patients had an unknown primary site. The 
clinicopathologic characteristics from this series are presented in Table 1.  The majority 
of patients were 50 years or older at the time of dissection (n=116, 69%).  Most patients 
had original primary tumors which were of intermediate thickness—between 1 and 4mm 
(n=108, 64%).  There were 18 patients (11%) who initially presented with thin (≤ 1mm) 
melanomas.  There were more ulcerated primary tumors than non-ulcerated primaries 
although there were a large number of patients who were missing data on ulceration—
again data on ulceration was not part of the AJCC staging system until 2002.  The median 
number of examined nodes was 22 (range=5—123, mean=26.1).  The median number of 
positive nodes was 2 (range = 1—55, mean = 4.0).  The largest group of patients (n=76, 
45%) were categorized as N1, while 39% and 15% were N2 and N3, respectively. 
 According to previous work, patients were assigned to groups based on LNR.  
The majority of patients were in group 1 (LNR ≤ 10%, n=93, 55%).  There were 45 and 
30 patients in groups 2 (10-25%) and 3 (>25%), respectively.  Among patients with 
AJCC TNM N1 stage (n=76), the lowest lymph node ratio (group 1) had the most 
patients (n=37, 49%).  There were 29 patients (38%) in group 2 and 10 patients in group 
3 (Figure 1).  For patients with N2 stage disease (n=66), there were 38 patients in ratio 
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group 1 (58%), 15 in group 2 (23%), and 13 patients (20%) in the highest LNR group.  
Finally, for patients with N3 regional disease (n=26), there were 18 patients (69%) with a 
ratio ≤ 10%. (These 18 patients had a median of 54 lymph nodes removed, with a 
maximum of 123).  In group 2, there was one patient, while in group 3, there were seven 
patients (27%). 
 The median survival of the entire series was 34 months (95% CI 29-44) with 36% 
(95% CI 28%-44%) of patients surviving at least 5 years.  Using univariate analysis, age, 
sex, year of surgery, tumor thickness, and ulceration were not significant predictors of 
survival (Table 2).  One of the strongest predictors of overall survival (OS) was LNR 
>25% (HR=3.08, p<0.01).  A LNR between 10 and 25% was also an important predictor 
of survival (Table 2).  Other factors that were significant on univariate analysis were type 
of treatment, number of positive nodes, and LN basin dissected (patients who had LND 
for cervical metastases had decreased survival compared to those with axillary 
metastases.) The total number of examined or excised lymph nodes was not an important 
factor for survival (HR=1.0 per node, p = 0.83).  Finally, we saw a borderline significant 
difference in survival depending on whether the indication for lymph node dissection was 
performed for a positive sentinel node compared to those who underwent dissection for a 
clinically positive lymph node basin (p = 0.08), as well as in primary sites with lower 
hazards in patients with either trunk or extremity versus head/neck (p = 0.10, p = 0.09 
respectively.) 
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Of the 3 different multivariate models concerning LNR and total number positive 
nodes variables (namely:  both LNR and total number positive nodes in the model;  LNR 
alone;  total number positive nodes alone;  these three models with the other variables as 
described in methods), the model with LNR alone had the smallest AIC (Akaike 
information criterion:  833.6, 830.2, and 836.2, respectively). This multivariate analysis 
showed that the only factors that were predictive of overall survival were LNR and type 
of treatment. Those with a LNR >25% had a 4-fold higher risk of dying compared to 
those with a LNR <10% (p<0.01). Type of treatment is globally significant, but looking 
at the individual levels show that of the four types of treatment compared to 
none/unknown, only chemotherapy medications had an even marginally significant 
hazard ratio (H.R. = 1.90, p = 0.08).  LN basin was not a globally significant factor in the 
model (p = 0.20), however, those with more than one nodal basin involved had twice the 
risk of dying (H.R. = 2.12, p = 0.05) compared to axillary.  When included in the model 
with LNR, as an alternate analysis, the total number of positive nodes was not significant, 
p = 0.75, although this is somewhat obscured by the fact that this value is used to 
compute (and may be collinear with) LNR.   LNR was still significant, p < 0.024.) 
 In terms of median and 5-year survival (Figure 2, Table 3) of patients by LNR, we 
found a significant difference among the 3 LNR groups.  Patients in group 1 had a 
median survival of 77 months (95% CI 43, ∞) with estimated 5-year survival of 52% 
(95% CI 40%-63%).  Patients in groups 2 and 3 had 5-year survivals of 24% and 0%, 
respectively.  The separation of the 3 survival curves was persistent throughout the entire 
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course of follow-up.  We also looked at median and overall survival based on number of 
positive nodes (AJCC N stage N1, N2, and N3); these are presented in Figure 3.  As you 
can see from this figure, there is a difference in survival with N1 patients surviving a 
median of 52 months compared to 26 months for those with N3 disease (Table 3).  
However, the survival curves of the N1 and N2 patients do not have a lot of separation 
from each other like we see with the plots for LNR.  Using AIC, we were able to 
determine that the LNR model provided a better fit for overall survival than AJCC N 
Stage. 
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DISCUSSION 
 Melanoma has been increasing in frequency for the past several years and has 
now become the seventh most common malignancy diagnosed in the United States.  
Patients with stage III melanoma cover a wide range of disease spectrums from those 
with microscopically positive lymph nodes found with sentinel node mapping and a non-
ulcerated primary (Stage IIIa) who have an estimated 5-year survival rate of ~70% 
according to AJCC data 2 down to patients with ulcerated primary tumors and clinically 
positive nodal basins with more than 3 nodes involved.  These patients have estimated 5-
year survivals down to 13% 12.   
 This vast heterogeneity in survival for stage III patients causes limitations in the 
applicability of the current staging system in terms of making treatment decisions and 
stratifying patients for adjuvant therapy and clinical trials.  Currently the only treatment 
approved by the FDA in the US for the adjuvant treatment of patients with stage III 
melanoma is Interferon-alpha-2b.  Multiple studies have shown this treatment to increase 
relapse free survival but there has been little impact on overall survival.  Most of these 
studies were completed at a time when the majority of patients diagnosed with stage III 
disease had macroscopic or clinically positive disease.  Clearly these patients are at 
higher risk and may benefit more from treatment.  However, the patients diagnosed with 
microscopic disease on sentinel node biopsy or with minimal lymph node involvement 
probably represent a lower risk group.  For example, in the recently completed Sunbelt 
Melanoma Trial13, patients with one positive lymph node by sentinel node biopsy were 
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randomized to completion LND versus LND plus one year of standard adjuvant therapy 
with Interferon-a.  This trial showed no difference in disease-free or overall survival 12 
for this group of patients that could be considered lower risk.   
 Therefore, it is imperative that we find more reliable prognostic factors which 
could be of greater clinical benefit in providing patients with the highest chance of cure.  
One prognostic factor which has become more prevalent in patients with lymph node 
positive cancer is that of the ratio of metastatic to examined nodes or LNR (also called N-
ratio).  There are several examples in the literature which have demonstrated the 
importance of LNR in determining survival.  In a gastric cancer study, Bando et al 
divided 650 patients into four groups based on LNR. These ratios were 0, 0 to 10, 10 to 
25, and more than 25; the 5-year survival rates were 86%, 68%, 35%, and 16%, 
respectively, and LNR was an independent prognostic factor 8.  Another recent study by 
Rossi et al, was the first to demonstrate the prognostic significance of LNR in patients 
with stage III melanoma 5.  In this study, patients were divided into 3 groups based on 
LNR of ≤10%, 10 - <25%, and >25%.  These authors also demonstrated that LNR was an 
independent prognostic factor for survival.  They also found that TNM stage was the 
strongest independent predictor of survival 5.  The only primary tumor dependent factor 
which was significant on multivariate analysis was tumor thickness measured as a 
continuous variable.   
 In our study, we too found that LNR was an independent predictor of overall 
survival.  In fact, we did not determine any variables related to the primary tumor to be 
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predictive of overall survival.  Our study was slightly different from that of Rossi et al in 
that we categorized tumor thickness into 4 groups as it is in the current AJCC 
classification.  This is similar to findings of the group at John Wayne Cancer Institute 
who found that the most important factors for survival in patients with stage 3 melanoma 
are those found at the time of lymph node dissection—number of positive nodes and 
whether lymph nodes were clinically palpable 4.  Tumor thickness as a primary related 
factor was still significant but less so in their model.  The majority of patients in our 
series were treated before sentinel lymph node biopsy became standard of care in 
melanoma treatment. Therefore, only 61 (31%) of patients underwent completion lymph 
node dissection for a positive sentinel lymph node. We did find that the indication for 
lymph node dissection was of borderline significance on univariate analysis but lost this 
trend on multivariate analysis (p=0,32). We acknowledge that in the current era, the 
majority of regional lymph node dissections are performed for positive sentinel lymph 
nodes and that the current study may not be completely applicable. We are currently in 
the process of analyzing a more current and larger database to examine this phenomenon. 
 The most comprehensive analysis to date on the impact of LNR in melanoma was 
published recently by the Melanoma Institute of Australia10.In this analysis, the authors 
used the previous cutoffs set out by Rossi et al (<10%, 10-25%, and >25%) and 
confirmed the importance of LNR in a large melanoma population (n=1514) with 
standardized surgical quality. Furthermore, they showed that LNR also allowed for 
substaging of the AJCC N3 patients.  There was no separation of patients in this analysis 
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based on indication for regional LND even though their series spanned the era of 
therapeutic versus completion dissection. 
 In a recent analysis of the SEER database for patients undergoing therapeutic 
LND for melanoma, Xing et al evaluated the importance of LNR by examining a LNR 
threshold above which disease-specific survival significantly decreases.  They determined 
these thresholds to by 7%, 13%, and 18% for neck, axillary, and inguinal regions, 
respectively 6.  In their multivariate analysis, patients who had a LNR less than the 
threshold had a 50% reduction in their hazard ratio for disease-specific death (p<0.001). 
6
. One of the limitations of this study is that there is a relatively short median follow-up 
time of 3 years; additionally, the SEER database does not have data on adjuvant 
treatment. 
Some people may also be troubled by the fact that a primary tumor characteristic 
such as ulceration was not a significant factor for survival.  In the study of Balch et al of 
the AJCC database, these authors found 5 factors which were independent predictors of 
survival in 1200 patients with lymph node metastases. These included the number of 
metastatic nodes, the tumor burden (micro- vs. macroscopic), ulceration of the primary, 
age, and the site of the primary tumor 2.  However, since the majority of patients in this 
study underwent lymph node dissection for clinically positive lymph node basins at some 
point distant from their primary tumor resection, it would seem intuitive that survival 
should be influenced primarily by characteristics of the stage III disease, such as the 
number of positive nodes and lymph node ratio.  As our group has pointed out 
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previously14, the Balch study is somewhat flawed by the fact that survival was measured 
from the date of diagnosis of the primary tumor instead of from the date of lymph node 
dissection.  For this reason, characteristics of the primary, such as ulceration probably 
played a bigger role in their analysis. We also recognize that approximately one-third of 
patients did not have data regarding ulceration status in our series. Unfortunately, a large 
proportion of our patients are referred from outside dermatologists after undergoing 
primary removal and data regarding ulceration was not universally reported prior to 2002 
when it was first made part of the AJCC staging system. It would be very difficult to go 
back and analyze all of these specimens for ulceration. We acknowledge that this is a 
limitation in our study. 
 Finally, in looking at survival curves based on LNR group vs. N category, we see 
that there is a much better discrimination between patients using LNR than with N stage 
(Figures 2 and 3).  As the LNR increased from ≤ 10% to over 25%, the 5-year survival 
correspondingly dropped off from 52% (95% CI 40%-63%) to 24% (95% CI 11%-40%) 
to 0%.  However, 5-year survivals by N stage were similar for N1 and N2 disease (48% 
(95% CI 35%-60%) and 44%, (95% CI 36%-60%), respectively).  Therefore, we feel that 
the ratio of positive to examined lymph nodes (LNR) should play a more prominent role 
in the staging system for melanoma and serve as important stratification for patients 
undergoing adjuvant therapy for stage III melanoma.  We hope to further validate these 
findings in larger patient datasets in the future.
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FIGURE LEGENDS: 
Figure 1: Demonstrates the breakdown of patients in AJCC N1, N2, and N3 categories by 
the corresponding lymph node ratio. 
 
Figure 2: Kaplan-Meier survival curve which demonstrates overall survival as determined 
by lymph node ratio (<10%, 10-25%, and >25%) with a clear decrement in survival with 
increasing ratio. This relationship is highly statistically significant (p<0.0001). 
 
Figure 3: Kaplan-Meier curve demonstrating the relationship between survival and AJCC 
N stage (N1, N2, and N3). Here you can see that there is a statistically significant 
relationship between increasing N stage and worsening survival. However, there is not as 
much separation of curves as demonstrated in Figure 2. 
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